Supplementary Online Content
|
|
|
- Elmer Powell
- 5 years ago
- Views:
Transcription
1 Supplementary Online Content Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatol. Published online June 25, doi: /jamadermatol etable 1. Patients with abnormal transient elastography and/or procollagen III peptide level results etable 2. Patients with abnormal FibroTest results and/or procollagen III peptide level results etable 3. Patients with abnormal procollagen III peptide level results who did not proceed to liver biopsy This supplementary material has been provided by the authors to give readers additional information about their work American Medical Association. All rights reserved. 1
2 etable 1. Patients with abnormal Transient Elastography and/or Procollagen III Peptide level results A Patients with abnormal transient elastography results Patients with abnormal TE BMI PsA SH MTX dose, g Duration on MTX, years serially pre TE Liver Biopsy, Fibrosis Stage No s F 32 N N N N N N 10.5 ND ND No s F 29.1 N Y N N ALT 59 Y 9.9 F0 3a No s M 29.8 N N N N N N 8.7 F0 ND No s F 22.4 N N N N N N 7.6 ND ND No s M NR N Y N N N Y 9.1 F3 ND No s F 19.8 N N N N N N 7.1 F1-F2 ND No s M 27.6 N N N N N ND 9.9 F0 ND No s F 42.9 N N N N N N 11.3 F0 ND No s F 22 N N N N N ND 9.1 F0 ND 2014 American Medical Association. All rights reserved. 2
3 etable 1. Patients with abnormal Transient Elastography and/or Procollagen III Peptide level results B. Patients with abnormal procollagen III peptide level results pre transient elastography Abnormal pre TE BMI PsA S H MTX dose, g Duration on MTX, years pre TE No s F 29.1 N Y N N ALT 59 Y 9.9 F0 3a No s M NR N Y N N N Y 9.1 F3 ND No s F 34.7 Y Y N N N Y Invalid F1-F2 3b No s F 29.4 N Y N N N Y 6.5 F0 1 No s F 63.6 N N N N N Y Failed F0 ND No s M 30.1 N Y N N N Y 4.9 F0 1 No s M 28.7 N N N N N Y 4.3 F0 ND No s F 30.5 N N N N N Y 6.4 F0 ND No s M 26.5 N N N N N Y 4.5 F1-F2 ND Liver Biopsy, Fibrosis stage transient elastography; BMI, body mass index; PsA, psoriatic arthritis; SH, steatohepatitis; MTX, methotrexate;, diabetes mellitus;, liver function tests;, procollagen III peptide; F, female; M, male; N, no; Y, yes; ND, not done; NR, not recorded; ALT, alanine aminotransferase. s were performed at a later time to Transient Elastography American Medical Association. All rights reserved. 3
4 etable 2. Patients with abnormal FibroTest results and/or Procollagen III Peptide level results A. Overall abnormal results Patients with abnormal FibroTest results on MTX BMI PsA SH MTX dose, g Duration on MTX, years serially pre Fibrotes Liver Biopsy, Fibrosis stage No s M NR N Y N N N Y 9.1 F3 ND No s F 19.8 N N N N N N 7.1 F1-F2 ND No s F 34.7 Y Y N N N N Invalid F1-F2 3b No s M 25.2 N Y N N N N 5.3 F3 ND No s M 25.7 N N N N N ND 6.8 F3 ND No s F 29.9 N N N N N ND Invalid F2 ND No s M 24.9 N N N N N ND Invalid F1-F2 ND No s M 21.5 N N N N N ND 6.3 F1-F2 ND No s M 31.6 Y Y N N N ND 6.1 F1-F2 ND No s M 26.5 N N N N N ND 4.5 F1-F2 ND No s M 38.5 Y N N N N ND NR F1-F2 ND 2014 American Medical Association. All rights reserved. 4
5 etable 2. Patients with abnormal FibroTest results B. Patients with abnormal procollagen III peptide level results pre FibroTest Patients with abnormal results pre FibroTest BMI PsA SH MTX dose, g Duration on MTX, years serially pre FibroTest No s M NR N Y N N N Y 9.1 F3 ND No s F 30.5 N N N N N Y 6.4 F0 ND No s F NR Y N N N N Y NR F0 1 Liver Biopsy, Fibrosis stage Age, MTX dose and duration adjusted in Table 3 compared to Table 2 due to time interval between TE and FibroTest. BMI, body mass index; PsA, psoriatic arthritis; SH, steatohepatitis; MTX, methotrexate;, diabetes mellitus;, liver function tests;, procollagen III peptide; F, female; M, male; N, no; Y, yes; ND, not done; NR, not recorded. s were performed at a later time to Transient Elastography American Medical Association. All rights reserved. 5
6 etable 3. Patients with abnormal procollagen III peptide level results who did not proceed to liver biopsy Persistently abnormal Reason for not proceeding to liver biopsy Management No. 68 Male in his 80 s, clinical Continued methotrexate decision No. 16 Patient refused Changed to fumaric acid esters No. 63 Patient refused Changed to fumaric acid esters No. 72 Patient refused Changed to fumaric acid esters No. 46 Patient refused Changed to etanercept, procollagen III peptide American Medical Association. All rights reserved. 6
Break the Liver Biopsy Habit
Break the Liver Biopsy Habit Dirk Elston MD Professor and Chairman Department of Dermatology and Dermatologic Surgery Medical University of South Carolina No conflict of interest Father of one of my nurses:
Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
Psoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
Research Article Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role?
BioMed Research International Volume 2016, Article ID 7963972, 6 pages http://dx.doi.org/10.1155/2016/7963972 Research Article Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors
ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
Supplementary Online Content
Supplementary Online Content Ross NA, Chung H-J, Li Q, Andrews JP, Keller MS, Uitto J. Pityriasis rubra pilaris: a case series of patients. Published online March 9, 26. JAMA Dermatol. doi:./jamadermatol.26.9.
Supplementary Tables. Psoriasis a
Supplementary Tables Supplementary Table S1 Age-sex distribution of patients with psoriasis and PPP subdivided by the department specified in a claim with a diagnosis code of psoriasis and PPP in Japanese
Autoimmune Diseases and Therapeutic Approaches
Autoimmune Diseases and Therapeutic Approaches Open Access Received: Sep 12, 2014 Accepted: Oct 10, 2014 Published: Oct 14, 2014 http://dx.doi.org/10.14437/adtaoa-1-104 Review Aze Wilson, Autoimmune Dis
HEPATIC FIBROSIS AND CIRrhosis
STUDY Reliability of the Roenigk Classification of Liver Damage After Methotrexate Treatment for Psoriasis A Clinicopathologic Study of 160 Liver Biopsy Specimens Maartje A. M. Berends, MD; Martijn G.
Non-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
Liver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
Supplementary Online Content
Supplementary Online Content Foley P, Gordon K, Griffiths, CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized
Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
Fatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
Insights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
This questionnaire was used both during the face-to-face interviews with the
Additional file 1: Primary research questionnaire This questionnaire was used both during the face-to-face interviews with the dermatologists and during the expert panel 1. During the last month, how many
Hepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
CLINICAL STUDIES. Liver International ISSN
Liver International ISSN 1478-3223 CLINICAL STUDIES Biochemical and biophysical assessment of MTX-induced liver brosis in psoriasis patients: predicts the presence and Fibroscan s predicts the absence
Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning
Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,
The Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
Module 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
Table SIII. Evidence table. First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), Date of evaluation
Table SIII. Evidence table First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), 2009 (n = 39 a ) van Lümig (13), 2010 (n = 30 a ) Warren (14), 2010 (n = 46 a ) Retrosp b Adalimumab
2016 PQRS. Rheumatiod Arthritis Me asures Group. Measures. Reporting Instructions
Measures #108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy #128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan #131 Pain Assessment
3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Enbrel (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
Pharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Enbrel (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
Psoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
Transient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
The Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
Supplementary Online Content
Supplementary Online Content Marklund M, Carlberg B, Forsgren L, Olsson T, Stenlund H, Franklin KA. Oral appliance therapy in patients with daytime sleepiness and snoring or mild to moderate sleep apnea:
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
Supplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
Supplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
Journal Watch. Reviewed by YK Lai, CY Chan, CK Kwan, MYM Wat
Hong Kong J. Dermatol. Venereol. (2014) 22, 155-160 Reviewed by YK Lai, CY Chan, CK Kwan, MYM Wat Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at
Insights from the Clalit Health Services database about Psoriasis Research using BIG DATA Arnon D. Cohen, MD, MPH, PHD
Insights from the Clalit Health Services database about Psoriasis Research using BIG DATA Arnon D. Cohen, MD, MPH, PHD Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences,
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate BMJ Jenny H Humphreys, Alexander Warner, Ruth Costello, Mark Lunt, Suzanne M M Verstappen,
USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Authors: Jennifer Gallacher, 1 *Stuart McPherson 1,2 1. Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman
Clinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
Monitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
Psoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
1 x weekly 50 mg. Consumption:
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
Supplementary Online Content
Supplementary Online Content Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists
DOI: 10.1111/jdv.12495 JEADV ORIGINAL ARTICLE Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists R. Gyulai, 1,2 M. Bagot, 3 C.E.M. Griffiths, 4 T. Luger,
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
Supplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis
Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis Krishna Menon, RCM, PhD, VMD, President of Research and Chief Scientific Officer MEDICAL DERMATOLOGY THERAPEUTIC R&D AND
In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates
Screening cardiac patients for advanced liver disease
HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD
Original Article. Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection
Original Article Phrommee N, et al. 15 Six Month Follow-up of Liver Stiffness Measurement in Untreated Chronic Hepatitis C With or Without HIV Co-infection Phrommee N Leerapun A Pisespongsa P Chitapanarux
Rheumatoid Arthritis Remedies: Herbs, Supplements And Vitamins By Jeffrey Fisher
Rheumatoid Arthritis Remedies: Herbs, Supplements And Vitamins By Jeffrey Fisher If looking for a ebook Rheumatoid Arthritis Remedies: Herbs, Supplements and Vitamins by Jeffrey Fisher in pdf form, then
Management of Patients with Past or Present Hepatic Abnormalities
S21 Management of Patients with Past or Present Hepatic Abnormalities Evidence Based Medicine Official recommendations Expert opinion Course of action before tocilizumab therapy in patients with a history
The use of methotrexate in treatment of moderate to severe psoriasis
Hong Kong J. Dermatol. Venereol. (2009) 17, 13-19 Review Article The use of methotrexate in treatment of moderate to severe psoriasis WY Leung and KH Lau Psoriasis is a common, chronic and non-infectious
Psoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center
Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis
Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2019 Origination: 2/2017 Next Review: 2/2020 Policy Blue Cross and
Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
Update on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
Supplementary Online Content
Supplementary Online Content Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Supplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
Study population The study population comprised patients with psoriasis who were receiving long-term methotrexate.
Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis Chalmers R
Supplementary Online Content 2. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on
Supplementary Online Content 2 Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated
Arthritis Rheumatism Psoriasis
Arthritis Rheumatism Psoriasis 1 / 6 2 / 6 3 / 6 Arthritis Rheumatism Psoriasis You may think that arthritis is a single condition, but there are many forms of arthritis. Each type can be caused by different
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2018 Origination: 2/2017 Next Review: 2/2019 Policy Blue Cross and
New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV
New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV Jidong Jia, MD, PhD Beijing Friendship Hospital, Capital Medical University 2016-3-14 Disclosure Consultation for Abbvie
The Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Professor of Medicine University of Chicago Chicago, Illinois Overview Initial assessment of liver disease How do you diagnose cirrhosis?
The Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
Hepatitis C Virus Infection in Diabetes Mellitus Patients
599 Hepatitis C Virus Infection in Diabetes Mellitus Patients Han Ni*, Soe Moe, Aung Htet 1 Assistant Professor, Department of Medicine, Melaka Manipal Medical College, Malaysia 2 Associate Professor,
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vosevi) Reference Number: CP.HNMC.41 Effective Date: 07.26.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
Elements for a Public Summary. Overview of Disease Epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Toxicity of Folic acid antagonists Despite having a low frequency of major toxicity, low dose Methotrexate (MTX, folic acid antagonist)
Supplementary Online Content
Supplementary Online Content Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of Noninsulin Antidiabetic Drugs Added to Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes.
Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
Management Of Psoriasis (Current Problems In Dermatology, Vol. 38) READ ONLINE
Management Of Psoriasis (Current Problems In Dermatology, Vol. 38) READ ONLINE on current issues in dermatology. Dr. Camisa is board certified in dermatology and mouth and lips. Dr. Camisa is a leading
Supplementary Online Content
Supplementary Online Content Drury KE, Schaeffer M, Silverberg JI. Association between atopic disease and anemia in US children. JAMA Pediatr. Published online vember 30, 2015. doi:10.1001/jamapediatrics.2015.3065.
*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor
APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor
SMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha
Coccidioidomycosis in Rheumatologic Patients. Susan E. Hoover, MD
Coccidioidomycosis in Rheumatologic Patients Susan E. Hoover, MD The problem Prevalence of rheumatoid arthritis is 1% Population of Arizona is 6 million At least 150,000 new cocci infections yearly DMARDs
NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
Supplementary Online Content
Supplementary Online Content Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in cardiology practices
2. Does the patient have a diagnosis of Crohn s disease? Y N
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Stelara (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Supplementary Online Content
Supplementary Online Content van Beek N, Lüttmann N, Huebner F, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol. Published
MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Medical Policy BCBSA Ref. Policy: 2.04.41 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies
Breakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING